close
Use this form to share this article or news release from the Town of Miami Lakes website with a friend.
Title: Miami Lakes Based HeartWare Wins Prestigious Beacon Council Award
Share!
Thanks for sharing! Your message has been sent!
Click here to close window.
  • Pic 1
  • Pic 2
  • Pic 3
  • Pic 4
  • Pic 5
  • Pic 6
  • Pic 7
  • Pic 8
  • Pic 9
  • Pic 10
TOWN OF MIAMI LAKES NEWS
×

Warning

JUser: :_load: Unable to load user with ID: 67
243px-All-America City LogoThe Town of Miami Lakes is pleased to announce that global medical device company, HeartWare, with one if its two operating and manufacturing activities based in Miami Lakes, has been awarded a prestigious award from the Beacon Council for leadership and growth in the Life Sciences & Healthcare Industry.
For Immediate Release
March 19, 2015
Contact: Nicole Lesson
Tel: 305-364-6100
E-mail:  lessonn@miamilakes-fl.gov
 
 
Miami Lakes Based HeartWare Wins Prestigious Beacon Council Award
 

Miami Lakes, FL - The Town of Miami Lakes is pleased to announce that global medical device company, HeartWare, with one if its two operating and manufacturing activities based in Miami Lakes, has been awarded a prestigious award from the Beacon Council for leadership and growth in the Life Sciences & Healthcare Industry.

Each year, the Beacon Council honors companies and individuals who have made outstanding contributions to Miami-Dade County’s economy in the areas of job creation, business expansion, corporate citizenship and leadership. HeartWare will be presented with the award at the 13th annual Beacon Awards on April 2, 2015 at the University of Miami Students Activities Center in Coral Gables.

HeartWare is a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life. The company’s innovative technologies are creating advances in the miniaturizations of Ventricular Assist Devices (VADs) leading to less invasive surgical procedure and increasing the patient population who may be suitable for VAD therapy.